BIOMARIN PHARMACEUTICAL

biomarin-pharmaceutical-logo

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

#People #Financial #Event #Website #More

BIOMARIN PHARMACEUTICAL

Social Links:

Industry:
Biotechnology Developer Platform

Founded:
1997-03-01

Address:
San Rafael, California, United States

Country:
United States

Website Url:
http://www.biomarin.com

Total Employee:
1001+

Status:
Active

Contact:
415-506-6700

Email Addresses:
info@bmrn.nl

Total Funding:
585.8 M USD

Technology used in webpage:
IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving Mobile Non Scaleable Content Nginx Amazon IPv6 JsDelivr Microsoft Azure DNS



Current Advisors List

william-young_image

William Young Member of the Board of Directors @ BioMarin Pharmaceutical
Board_member

kenneth-m-bate_image

Kenneth M. Bate Board of Directors @ BioMarin Pharmaceutical
Board_member

david-pyott_image

David Pyott Member of the Board of Directors @ BioMarin Pharmaceutical
Board_member

Current Employees Featured

chieze-ibeneche-nnewihe_image

Chieze Ibeneche-Nnewihe
Chieze Ibeneche-Nnewihe Director, Business Development and Corporate Strategy @ BioMarin Pharmaceutical
Director, Business Development and Corporate Strategy
2020-08-01

not_available_image

Geoff Nichol
Geoff Nichol CMO & SVP, Global Clinical Development @ BioMarin Pharmaceutical
CMO & SVP, Global Clinical Development
2016-11-01

chris-houlder_image

Chris Houlder
Chris Houlder Head of Global Cybersecurity @ BioMarin Pharmaceutical
Head of Global Cybersecurity
2020-09-01

kevin-eggan_image

Kevin Eggan
Kevin Eggan Head of Research and Early Development @ BioMarin Pharmaceutical
Head of Research and Early Development
2020-10-01

not_available_image

Victoria Sluzky
Victoria Sluzky Senior VP, Global Quality and Development @ BioMarin Pharmaceutical
Senior VP, Global Quality and Development
2003-02-01

diane-white_image

Diane White
Diane White Exec. Director, Head of Global Project Management @ BioMarin Pharmaceutical
Exec. Director, Head of Global Project Management
2019-10-01

jean-jacques-bienaime_image

Jean-Jacques Bienaime
Jean-Jacques Bienaime Chairman of the Board & Chief Executive Officer @ BioMarin Pharmaceutical
Chairman of the Board & Chief Executive Officer
2005-05-01

brinda-balakrishnan_image

Brinda Balakrishnan
Brinda Balakrishnan Group Vice President, Corporate and Business Development @ BioMarin Pharmaceutical
Group Vice President, Corporate and Business Development
2015-01-01

nicole-zilveti_image

Nicole Zilveti
Nicole Zilveti Development Sciences Operations Sr. Admin @ BioMarin Pharmaceutical
Development Sciences Operations Sr. Admin
2016-06-01

paul-stanley_image

Paul Stanley
Paul Stanley Senior Director of Facilities @ BioMarin Pharmaceutical
Senior Director of Facilities
2013-10-01

Founder


not_available_image

Christopher Starr

not_available_image

Grant Denison

Stock Details


Company's stock symbol is NASDAQ:BMRN

Acquisitions List

Date Company Article Price
2014-11-24 Prosensa Prosensa acquired by BioMarin Pharmaceutical 840 M USD
2013-01-07 Zacharon Pharmaceuticals Zacharon Pharmaceuticals acquired by BioMarin Pharmaceutical N/A
2010-08-17 Zystor Zystor acquired by BioMarin Pharmaceutical 115 M USD
2010-02-10 LEAD Therapeutics LEAD Therapeutics acquired by BioMarin Pharmaceutical 97 M USD
2009-10-26 Huxley Pharmaceuticals Huxley Pharmaceuticals acquired by BioMarin Pharmaceutical N/A
2002-02-07 Glyko Biomedical Glyko Biomedical acquired by BioMarin Pharmaceutical N/A

Newest Events participated

14th-annual-international-pediatric-orthopaedic-symposium_event_image Participated in 14th Annual International Pediatric Orthopaedic Symposium on 2017-11-28 as sponsor

abilities-expo-houston-2015_event_image Participated in Abilities Expo Houston 2015 on 2015-07-31 as exhibitor

Key Employee Changes

Date New article
2021-10-04 BioMarin snags Vertex VP as CMO a month after clinical snafu in gene therapy trial

Official Site Inspections

http://www.biomarin.com Semrush global rank: 1.68 M Semrush visits lastest month: 14.5 K

  • Host name: 13.107.246.40
  • IP address: 13.107.246.40
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Biomarin.com lookup results from whois.corporatedomains.com server:
  • Domain created: 13th-Aug-2014
  • Domain updated: 15th-May-2024
  • Domain expires: 2nd-Dec-2029 4 Years, 323 Days left
  • Website age: 10 Years, 152 Days
  • Registrar Domain ID: 1870947584_DOMAIN_COM-VRSN
  • Registrar Url: http://cscdbs.com
  • Registrar WHOIS Server: whois.corporatedomains.com
  • Registrar Abuse Contact Email: domainabuse@cscglobal.com
  • Registrar Abuse Contact Phone: 8887802723
  • Name server:
    • NS1-38.AZURE-DNS.COM
    • NS2-38.AZURE-DNS.NET
    • NS3-38.AZURE-DNS.ORG
    • NS4-38.AZURE-DNS.INFO

More informations about "BioMarin Pharmaceutical"

About Us | BioMarin

BioMarin RareConnections™ Program Established. Expanding on its decade-long track record of supporting eligible people with rare diseases in gaining access to the company’s medicines, the BioMarin RareConnections program …See details»

BioMarin Leadership Team - BioMarin Corporate

BioMarin Leadership Team. Alexander Hardy. President and Chief Executive Officer. G. Eric Davis. Executive Vice President, Chief Legal Officer. Greg Friberg. Executive Vice President, …See details»

BioMarin Pharmaceutical - Wikipedia

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturi…See details»

BioMarin Pharmaceutical Inc. - Investor Relations

6 days ago At Biomarin Pharmaceutical Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the …See details»

BioMarin Pharmaceutical - The Org

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. Industries. …See details»

BioMarin Pharmaceutical Inc. - Governance - Governance

The Board of Directors of BioMarin Pharmaceutical Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance …See details»

About Us - BioMarin Europe & Canada

You are about to leave the BioMarin.eu website and will be redirected to BioMarin’s global website owned and operated by our headquarters, BioMarin Pharmaceutical Inc., located in the United States. Please note that the …See details»

BioMarin Pharmaceutical - Crunchbase Company …

BioMarin Pharmaceutical reported record financial results for 2023, with earnings per share (EPS) increasing to US$0.89 from US$0.76 in FY 2022. The company also beat analyst estimates for its first quarter 2024 earnings. However, the …See details»

BioMarin Announces New R&D and Business Development …

Aug 21, 2024 These risks and uncertainties include, among others: Dr. Friberg and Dr. Sabry commencing employment as anticipated; possible complications associated with the …See details»

BioMarin, Canada

BioMarin RareConnections was created to help navigate some of the difficulties associated with serious rare genetic diseases by offering product support services throughout the treatment …See details»

BioMarin Simplifies Organizational Structure to Increase Efficiency

SAN RAFAEL, Calif., Oct. 6, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus …See details»

Support for Society | BioMarin

Supporting the communities where we live and work is central to who we are. We provide funding and support for a variety of activities, projects and events focused on patients, the scientific …See details»

BioMarin, Canada

Géré par le partenaire de BioMarin, Innomar Strategies, BioMarin RareConnections est un service privé, confidentiel et gratuit d’assistance aux personnes auxquelles des médicaments …See details»

BioMarin Announces Appointment of Cristin Hubbard as Chief …

Mar 7, 2024 This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements …See details»

BioMarin - Overview, News & Similar companies | ZoomInfo.com

Jun 20, 2024 BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on ... BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that …See details»

BioMarin, having retrenched, outlines plans for growth

Sep 4, 2024 BioMarin aims to bring in $4 billion in revenue by 2027, up from $2.4 billion last year, and maintain an annual growth rate in the mid-teen percentages through the decade, …See details»

Responsibility | BioMarin

As a global corporate citizen, BioMarin strives to operate in ways that contribute to the health of our environment, employees and communities. Learn More. Support for Society We’re …See details»

BioMarin - Overview, News & Similar companies | ZoomInfo.com

Who is BioMarin. BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical …See details»

Community Commitment | BioMarin

This BioMarin program focuses on developing BioMarin employees by providing a more senior BioMarin colleague to serve as a development partner for coaching and advice. Special …See details»

Chief R&D Officer Greg Friberg Discusses Career | BioMarin

Oct 28, 2024 BioMarin has an impressive track record of developing transformational medicines and what has set the company apart is a combination of three qualities: great science, great …See details»